KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Profit After Tax: 2009-2025

Historic Profit After Tax for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Profit After Tax rose 60.73% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.88%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Profit After Tax stood at -$7.7 million, which was down 406.86% from $2.5 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Profit After Tax high stood at $2.5 million for Q2 2025, and its period low was -$24.5 million during Q1 2025.
  • For the 3-year period, Arbutus Biopharma's Profit After Tax averaged around -$15.7 million, with its median value being -$17.9 million (2024).
  • In the last 5 years, Arbutus Biopharma's Profit After Tax crashed by 37.62% in 2021 and then skyrocketed by 112.74% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Profit After Tax stood at -$21.3 million in 2021, then fell by 2.87% to -$21.9 million in 2022, then rose by 11.95% to -$19.3 million in 2023, then surged by 35.11% to -$12.5 million in 2024, then skyrocketed by 60.73% to -$7.7 million in 2025.
  • Its Profit After Tax stands at -$7.7 million for Q3 2025, versus $2.5 million for Q2 2025 and -$24.5 million for Q1 2025.